Topic Listing for Warner Chilcott

Accounting Treatment Transaction Accounting Treatment Transaction See Page
Accounts Accounts Receivable
Accretion Preferred Stock Subsidiary Accrued Compensation Benefits
Accrued Expenses Acquired Business Faces Regulatory Other Risks Some Different
Acquired In-process Research Development Acquisition
Acquisition Ipo Equity Compensation Awards Acquisitions
Acquisitions Appraisal Rights Additional Fda Regulatory Requirements
Additional Termination Benefits Adjournment Shareholder Meetings
Adjusted Cash Net Income Loss Adjusted Ebitda
Adjustment Shares Adjustments
Adjustments Alterations Administration
Adoption Material Compensatory Plan Adverse Outcomes Outstanding Litigation Matters Negatively Impact Business
Advertising Promotion Advertising Promotional Costs
Advisory Services Monitoring Agreement After Reorganization Future Transfer Warner Chilcott Plc Shares
Alteration Capital Amended Restated
Amended Restated Employment Agreement Amended Restated Severance Agreement Senior Vice President
Amendment Amendment Governing Documents
Amendment Termination Amendment Termination Delay
Amendment Termination Management Incentive Plan Amendments Shareholders Agreements
Amortization Intangible Assets Amortization Intangible Assets Including Impairment
Annual General Meetings Annual Meeting
Annual Meeting Held 2008 Annual Meeting Matters
Annual Meeting Special Court-ordered Held 2009 Annual Meetings Shareholders
Annual Per-person Limitations Anthony Bruno-executive Vice President Corporate Development
Anti-takeover Provisions Appointment Rotation Removal Directors
Appraisal Rights Appraisal Rights See Page
Approval Creation Distributable Reserves Approval Equity Incentive Plan Amendments
Approval Management Incentive Plan Approval Scheme Arrangement
Asset Purchase Agreement Assumption Employee Stock Incentive Compensation Plans Awards
Assumptions Attachment
Audit Audit Committee
Audit Committee Report Auditors Remuneration
Authorized Share Capital Award Opportunities
Awards Equity Incentive Plan Awards Warner Chilcott Plc
Background Reasons Reorganization Barr Pharmaceuticals Inc
Base Salary Base Salary Benefits
Basis Presentation Basis Presentation Reporting Period
Because Sponsors Own Majority Outstanding Common Stock They Beneficial Ownership Reporting Compliance
Bermuda Bermuda Tax Considerations
Board Attendance Annual Meetings Board Committee Composition Management
Board Directors Recommend Vote Proposals Bonus Shares
Borrowing Powers Business Overview
Bye-laws Advance Notice Deadline California Securities Law Requirements
Calls Shares Capital Acquisitions Tax
Capital Expenditures Capital Structure
Capitalisation Profits Carl Reichel-president Pharmaceuticals
Cash Cash Bonuses
Cash Equivalents Cash Flow Presentation
Cash Flows Cash Net Income
Cash Net Income Adjusted Cash Net Income Loss Adjusted
Caution Concerning Forward-looking Statements Certain Relationships Related Transactions Director Independence
Certain Restrictions Change Mind After Vote
Change Vote After Return Proxy Card Changes Disagreements Accountants Accounting Financial Disclosure
Changes Internal Control Over Financial Reporting Changes Internal Controls Over Financial Reporting
Changes Laws Regulations Adversely Affect Results Operations Financial Changes Laws Regulations Affect Results Operations Financial Position
Changes Market Conditions Including Lower Expected Cash Flows Chief Executive Officer President Director
Choose Abandon Delay Transaction Cni
Co-promotion Agreement Co-promotion Agreement Sanofi-aventis
Co-promotion Licensing Agreements Code Business Conduct Ethics
Collaboration Matters Agreement Commitments Contingencies
Committees Board Directors Communication Board Directors
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Discussion Analysis
Compensation Program Philosophy Competition
Completion Transaction Compliance Code 162
Components Indebtedness Comprehensive Income
Concentration Credit Risk Reliance Significant Suppliers Major Products Concentration Credit Risk Significant Customers
Concentration Risk Conditions
Conditions Consummation Transaction Conference Call
Conference Calls Confidential Information
Conflicts Interest Consent Independent Auditors
Consent Independent Registered Public Accounting Firm Consolidated Statements Comprehensive Income
Consolidation Division Subdivision Contact
Contacts Contingencies
Contractual Commitments Controls Procedures
Corporate Governance Cost Sales Excluding Amortization Impairment Intangible Assets
Cost Sales Excluding Amortization Intangible Assets Costs Exit Disposal Activities
Costs Products Sold Court Sanction Scheme Arrangement
Court Sanction Scheme Arrangement See Page Creation Distributable Reserves
Creation Distributable Reserves See Page 103 Credit Agreement
Critical Accounting Policies Estimates Currency Translation
Customers Debt Service
Deeds Indemnification Deferred Loan Costs
Defined Contribution Plans Definite-lived Intangible Assets
Definitions Delays Production Material Adverse Impact Business
Delays Uncertainties Clinical Trials Government Approval Process New Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depreciation Amortization
Derivative Financial Instruments Derivatives
Derivatives Fair Value Financial Instruments Dermatology
Description Warner Chilcott Plc Shares Determination Payment Awards
Development Director Compensation
Director Independence Director Nominations Proposals Shareholders
Directors Directors Executive Officers Corporate Governance
Disclosure Beneficial Ownership Disclosure Controls Procedures
Disclosure Interests Shares Disqualification Directors
Distributions Dividends Divestitures-included Continuing Operations
Dividend Equivalent Rights Dividend Policy
Dividends Dividends Received Subject Irish Dividend Withholding Tax
Dividends Reserves Documents Incorporated Reference
Dovonex Dovonex Taclonex Commitments
Dovonex Taclonex Transactions Duration Dissolution Rights Liquidation
Duties Board Directors Earnings Per Share Eps
Effect Reorganization Potential Future Status Foreign Private Issuer Effective Date Transaction Time
Election Election Class Directors
Election Directors Elements Compensation
Eligibility Eligibility Participation
Employee Related Separation Other Cash Costs Employee Stock Incentive Compensation Plans Awards
Employees Employment
Employment Severance Agreements Enforcement Civil Liabilities Against Foreign Persons
Environmental Matters Equity Awards
Equity Compensation Plan Information Equity Grant Practices
Equity Incentive Awards Respect 2007 Performance Equity Incentive Awards Respect 2008 Performance
Equity Incentive Plan Amendments Equity Incentive Plan Benefits
Estimate Incremental Potential Payments Estimates
Evaluation Disclosure Controls Procedures Exact Name Registrant Specified Charter
Exchange Notes Extended Term Loans Exchange Shares
Executive Compensation Executive Officers
Executive Sessions Meetings Independent Directors Exercise Option Acquire Five-year License Barrs Anda References
Exercise Options Sars Exercise Price
Exhibits Expansion Leo Pharma Relationship
Expect Transaction Completed Expenses Related Ipo
Expenses Solicitation Expiration Options
Explanatory Fail Comply Government Regulations Subject Fines Sanctions Penalties
Fail Comply Reporting Payment Obligations Medicaid Rebate Program Fda Approval Requirements
Federal Income Tax Considerations Federal Income Tax Implications Equity Incentive Plan
Federal Securities Law Consequences Resale Restrictions Fees Paid Pricewaterhousecoopers Llp
Financial Condition Liquidity Capital Resources Financial Guidance Update
Financial Position Financial Statements
Financial Statements Businesses Acquired Financial Statements Exhibits
Financial Statements Supplementary Data Financing Commitments
Find Information Focuses Winning Consumer Health Care
Following Paragraph Quarter-end Financial Statements Following Paragraph Year-end Financial Statements
Foreign Currency Forfeiture Shares
Form 10-k Form 10-q
Form Committed Loan Notice Form Compliance Certificate
Form Issuer Agreement Form Swing Line Loan Notice
Former Address Former Name Address Changed Since Last Report
Forward Looking Statements Forward-looking Statements
Frustrating Action Ftc Lawsuits Regarding Exercise Option Five-year Exclusive License
Full Financial Guidance Future Expenses Realized
Future Sales Shares Depress Market Price Common Stock General
General Matters General Meetings
General Meetings Shareholders General Principles
Generic Products Compete Branded Pharmaceutical Approved Sales Adversely Goodwill
Goodwill Intangible Assets Government Regulation
Grant Grant Options Sars
Grant Share Award Grant Strip Shares
Grants Plan-based Awards Table Gross Payment
Gross-up Payment Growth Doryx Loestrin Estrace Cream Drives Solid Earnings
Growth Loestrin Estrace Cream Drive Solid Earnings Growth Promoted Product Revenue Reduced Expenses Continue Drive
Growth Promoted Products Reduced Operating Costs Continue Drive Growth Promoted Products Reduced Operating Costs Drive Solid
Guarantee Notes Guarantees
Guarantor Non-guarantor Condensed Consolidated Financial Information Having Separate Meetings
Held 2007 Held 2008
Held 2009 Hereby Consent Incorporation Reference Registration Statement Form S-8
Hereinafter Defined Historical Transactions Warner Chilcott Plcs Affiliates
History Development Hormone Therapy Product Liability Litigation
Householding Impact Ipo
Impairment Intangible Assets Important Information Shareholders
Important Information Shareholders Irish Withholding Tax Important Information Stockholders
Important Notice Regarding Availability Proxy Materials Annual Meeting Important Notice Regarding Internet Availability Proxy Materials Annual
Incentive Cash Bonuses Incentive Compensation Plans
Income Tax Dividends Paid Warner Chilcott Shares Income Taxes
Increase Shares Available Issuance Indebtedness
Indefinite-lived Intangible Assets Indemnification Agreements
Indemnification Directors Officers Insurance Indemnity
Independence Independent Auditors
Independent Auditors Report Index
Index Combined Financial Statements Procter Gamble Pharmaceuticals Index Consolidated Financial Statements
Inflation Information Directors
Information Reporting Backup Withholding Initial Public Offering
Initial Public Offering Ipo Inspection Books Records
Intangible Assets Goodwill Interest Income Expense
Interest Income Expense Net Interest Rate Risk
Interests Certain Persons Reorganization Inventories
Inventories Inventory Reserves Inventory
Investor Conference Call Investors Stockholders Urged Read Such Documents Filed Sec
Investors Stockholders Urged Read Such Proxy Statement Related Ipo Awards
Irish Income Tax Dividends Warner Chilcott Shares Decide Irish Stamp Duty Transfer Warner Chilcott Shares
Irish Takeover Rules Substantial Acquisition Irish Tax Chargeable Gains
Irish Withholding Tax Dividends Warner Chilcott Shares Decides Issuance Shares
Issued Share Capital Issuer Free Writing Prospectuses
Japan Licensing Agreement Sale Leases
Legal Matters Legal Name Formation Registered Office
Legal Proceedings Legally Transferring Plans
Legislative Action Congress Materially Adversely Affect Leo Pharma
Leo Transaction Liability Further Calls Assessments
License Supply Agreements Lien
Limitation Director Liability Liquidity Balance Sheet Cash Flows
Litigation Litigation Contingencies
Loestrin Femcon Patent Litigation Loestrin Femcon Settlement License Agreements
Loestrin Taclonex Fuel Strong Growth Revenue Cash Net Long-term Equity Incentives
Loss Services Members Senior Management Team Scientific Staff Making Paying Proxy Solicitation
Management Incentive Plan Management Shareholders Agreement Related Matters
Management Warner Chilcott Plc Managements Annual Report Internal Control Over Financial Reporting
Mandatory Bid Manufacturing Export
Manufacturing Supply Raw Materials Market Price Common Stock Volatile
Market Price Common Stock Volatile Cause Value Investment Market Price Dividend Information See Page 105
Market Warner Chilcott Plc Shares Differ Limited Material Tax Accounting Considerations
Material Tax Considerations Matter Tax Other Reasons Whether Hold Shares Beneficially
Members Board Directors Mergers Consolidations
Miscellaneous Provisions Move Tax Residence Bermuda Ireland Incorporate New Principal
Multi-employer Plans Name Person Filing Proxy Statement Other Registrant
Nature Operations Net Income
Net Income Cash Net Income Cni Adjusted
Net Income Loss Net Interest Expense
Net Periodic Benefit Costs Net Sales
New Accounting Pronouncements New Accounting Pronouncements Policies
New Legal Regulatory Requirements Make Difficult Obtain Expanded New Plan Benefits
New Product Launches New Products Fuel Strong Revenue Cash Net Income
New Senior Secured Credit Facilities News Release
Nominating Corporate Governance Committee Nonqualified Deferred Compensation
Nonqualified Deferred Compensation Plans Nontransferability Awards
Not Able Successfully Identify Develop Acquire License Market Not Check Smaller Reporting
Not Completed Evaluation Internal Controls Over Financial Reporting Not Realize Anticipated Opportunities Pgp Acquisition
Notes Notes Condensed Consolidated Financial Statements-
Notes Consolidated Financial Statements Notice General Meetings
Notices Number 1-33039
Number 33039 Number 333 134893
Number 333-134893 Number Authorized Shares
Off-balance Sheet Arrangements Officers
Operating Leases Option Exchange
Option Exercises Stock Vested Table Option Grants
Or- Order Board Directors
Order Directions Other
Other Benefits Other Business
Other Compensation Information Other Events
Other Financial Instruments Other Information
Other Matters Voted Annual Meeting Other Matters Voted Annual Meeting Special
Other Operating Expense Other Product Development Agreements
Other Regulation Other Revenue
Other Terms Awards Oversight Compensation Program
Overview Part
Part 2-the Scheme Part Financial Information
Part Other Information Parties Transaction
Passive Foreign Investment Rules Patent Matters
Patents Proprietary Rights Trademarks Patents Trade Secrets Proprietary Knowledge
Paul Herendeen Paul Herendeen-executive Vice President Chief Financial Officer
Payments Perceived Health Effects Estrogen Combined Estrogen-progestogen Hormone Therapy
Performance Awards Performance Awards Including Annual Incentive
Performance Goals Performance Graph
Perquisites Persons Respond Collection Information Contained Form Not Required
Pgp Acquisition Pharmaceuticals
Pharmaceuticals Business Plan Assets
Please Detach Along Perforated Line Mail Envelope Provided Please Vote Blue Black Ink Shown Here
Policies Procedures Dealing Review Approval Ratification Related Party Policies Procedures Dealing Review Approval Ratification Related Person
Potential Payments Termination Change-in-control Powers Board Directors
Powers Duties Directors Pre-approval Audit Permissible Non-audit Services Independent Auditors
Preapproval Audit Permissible Nonaudit Services Independent Auditors Predecessor Indebtedness
Preemption Rights Share Warrants Options Preferred Stock Subsidiary
Preliminary Prescription Drug Importation Canada Other Countries Increase Pricing
Presentation Financial Statements Pricing Pressures Third-party Payors Including Managed Care Organizations
Principal Accounting Fees Services Principal Products
Principles Consolidation Prior Product Development Agreements Leo
Prior Senior Secured Credit Facilities Pro Forma Condensed Combined Financial Information
Pro Forma Financial Information Proceedings Directors
Proceedings General Meetings Proceeds
Procter Gamble Procter Gamble Contacts
Procter Gamble Pharmaceuticals Product Acquisitions
Product Development Agreements Product Development Agreements Leo
Product Development Agreements Leo Pharma Product Liability Claims Recalls Harm Business
Product Pipeline Product Related Acquisitions
Products Properties
Property Plant Equipment Property Plant Equipment Net
Provision Benefit Income Taxes Provision Income Taxes
Provisions Applying Exercise Provisions Applying Grant
Provisions Bye-laws Delay Prevent Takeover Party Proxies
Proxy Solicited Behalf Board Directors Purchase Agreement
Purchase Commitments Purchased Shares
Purchases Subsidiaries Warner Chilcott Plc Purpose
Purpose Meeting Purpose Meetings
Quantitative Qualitative Disclosures Market Risk Quarterly Data
Quorum General Meetings Quorum Requirements
Reasons Reorganization See Page Recent Accounting Pronouncements
Recent Events Recent Highlights
Recent Legal Regulatory Requirements Make Difficult Obtain New Recitals
Reclassifications Recommendation Board Directors See Pages
Reconciliations Gaap Net Income Reconciliations Gaap Net Income Loss
Reconciliations Gaap Net Loss Record Date Quorum Requirements See Page 110
Record Dates Shareholder Meetings Recorded Significant Amount Intangible Assets Never Generate Returns
Redomestication Reduction Share Capital
Reduction Share Capital Increase Registrants Telephone Number
Registrants Telephone Number Including Area Code 441 292-0068 Regulation United Kingdom
Regulatory Matters Related Parties
Related Party Transactions Relevant Territories
Remainder Page Intentionally Left Blank Removal Directors
Reorganization Reorganization Affect Financial Reporting
Reorganization Affect Presence United States Reorganization Affect Warner Chilcotts Ability Access Capital Bank
Reorganization Affect Warner Chilcotts Current Future Operations Reorganization Affect Warner Chilcotts Presence Bermuda
Reorganization Impact Warner Chilcotts Ability Pay Dividends Buy Reorganization Material Impact Another Ability Acquire Warner Chilcott
Reorganization Not Allow Maintain Competitive Worldwide Effective Corporate Reorganization Result Additional Direct Indirect Costs Even Not
Report Independent Registered Public Accounting Firm Repurchases Equity Securities
Repurchases Redemptions Warner Chilcott Plc Required Satisfy Significant Contractual Obligation Sanofi
Required Vote Board Recommendation Required Vote See Pages
Research Development Research Development Activities
Restricted Share Award Agreement Restricted Share Grants
Restrictive Covenants Restructuring
Result Increased Shareholder Voting Requirements Ireland Relative Bermuda Results Operations 2006
Results Operations Financial Condition Revenue
Revenue Recognition Revenues Product Class Percentage Total
Revoke Proxy Right Repurchase
Rights Liquidation Rights Shareholder Change Result Transaction
Rights Shareholders See Page 117 Risk Factors
Risks Relating Business Roger Boissonneault
Roger Boissonneault-chief Executive Officer President Director Role Board Directors
Role Compensation Committee Executive Officers Consultants Decisions Role Compensation Committee Executive Officers Decisions
Royalty Arrangements Rule 14a-8 Proposal Deadline
S-1 S-2
S-3 S-4
Sale Other Disposition Warner Chilcott Plc Shares Sales Marketing
Sales Products Adversely Affected Consolidation Among Wholesale Drug Sample Notice Exercise
Sarbanes-oxley Act Savings Plan
Schedule Schedule 201a
Scheme Arrangement Approved Take Action Cancel Warner Chilcott Scope Discussion
Seal Seasonality
Securities Authorized Issuance Equity Compensation Plans Securities Exchange Act 1934
Securities Law Issues Transfer Restrictions Securities Litigation
Securities Registered Pursuant Act Securities Vesting Such According Particular Provisions Copy Agreement
Select Selling General Administrative Expense
Selling General Administrative Expenses Selling General Administrative Sga Expenses
Senior Secured Credit Facility Senior Subordinated Notes
Senior Vice President General Counsel Corporate Secretary Separate Meetings Shareholders Taking Place 2009
Separate Proxy Cards Annual Meeting Special Service Indebtedness Require Significant Amount Cash Ability Generate
Severance Severance Agreement Senior Vice President
Sga Expenses Share Awards
Share Option Award Agreement Share Power
Share Repurchases Redemptions Share Units
Shareholder Approval Business Combinations Appraisal Rights Shareholder Consent Action Without Meeting
Shareholder Own Majority Class Common Shares Shareholder Proposals
Shareholder Rights Plans Share Issuances Shareholders Agreements
Shareholders Ask Questions Shareholders Equity
Shareholders Equity Preferred Stock Subsidiary Shareholders Held 2009
Shareholders Own Majority Class Common Shares Shareholders Proposals
Shareholders Special Court-ordered Meeting Shareholders Subject Lock-up Letters
Shareholders Suits Shares Held Other Persons
Shares Held Outside Dtc Transferred Out Shares Held Resident Shareholders
Shares Held Residents Countries Not Relevant Territories Shares Held Residents Ireland
Shares Held Residents Relevant Territories Other United States Shares Held Through Dtc
Shares Voted Not Provide Proxy Signatures
Significant Amount Intangible Assets Never Generate Returns Expect Significant Events
Sources Uses Estimated 2009 Special Court-ordered Meeting Shareholders
Special Limitations Isos Special Meeting
Special Meetings Shareholders Special Regarding Forward-looking Statements
Sponsor Shareholders Agreement Stamp Duty
Stock Appreciation Rights Stock Exchange Listing
Stock Exchange Listing See Page 116 Stock Options
Stock-based Compensation Stock-based Compensation Connection Ipo
Strategic Relationship Leo Pharma Strategic Transactions
Strategy Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Subsequent Events Other Subsidiaries Registrant
Substantial Acquisition Rules Substantial Amount Indebtedness Adversely Affect Cash Flow Ability
Summary Summary Compensation Table
Summary Pro Forma Financial Information Summary Significant Accounting Policies
Supplemental Financial Information Supplemental Indenture
Supplemental Indenture Eliminate Dual Reporting Companies Table Contents
Taclonex Tax Consequences Holders
Tax Consequences Owning Warner Chilcott Plc Shares Tax Consequences Transaction
Tax Consequences Warner Chilcott Limited Plc Tax Considerations See Page
Taxation Distributions Taxing Authorities Reallocate Taxable Income Among Subsidiaries Increase
Term Equity Incentive Plan Termination
Termination Employment Cause Termination Employment Without Cause Good Reason Event Death
Termination Options Sars Termination Prior Agreement Terms Employment
Termination Service Terms Exchanging Leo 80185 Body Indication New Product
Terms Plan Terms Senior Secured Credit Facility Indenture Governing Notes
Terms Senior Secured Credit Facility Indenture Governing Outstanding Trade Warner Chilcott Limited Shares Between Date Proxy
Trademarks Trademarks Patents Other Intellectual Property Valuable Assets Unable
Transaction Affect Effective Tax Rate 2009-or Expectations Later Transaction Affect Stock Exchange Listing Warner Chilcott Shares
Transaction Costs Transaction Dilute Economic Interest Warner Chilcott
Transaction Summary Transaction Taxable
Transaction Taxable Warner Chilcott Limited Plc Transactions Between Sponsors Affiliates
Transactions Management Transactions Others
Transfer Registration Shares Transfer Shares
Transition Services Agreement Transmission Shares
Treatment Certain Irish Taxes Types Awards
United Kingdom Law Requirements United Kingdom Tax Approved Options
United States Unregistered Sales Securities
Unresolved Staff Comments Unsecured Senior Subordinated Notes Due 2015
Untraced Holders Vacancies Board Directors
Valuation Goodwill Intangible Assets Valuation Qualifying Accounts
Variation Class Rights Attaching Shares Vesting
Vesting Granted Strip Shares Vesting Restricted Shares
Voluntary Bid Requirements Make Cash Offer Minimum Price Vote
Vote Annual Meeting Vote Beneficial Holder Whose Shares Held Street Name
Vote Beneficial Holder Whose Shares Held Through Bank Vote Holder Record Whose Shares Registered Name
Vote Important Vote Person Annual Meeting
Vote Person Annual Meeting Rather Completing Proxy Card Vote Person Annual Meeting Special
Vote Proxy Registered Holder Vote Required Approval
Vote Shares Held Street Name Votes Counted
Votes Present Hold Annual Meeting Special Votes Present Hold Meeting
Voting Voting Rights
Warner Chilcott Warner Chilcott Acquires Pgs Global Pharmaceuticals Business
Warner Chilcott Announces Receipt Fda Response Citizen Petition Warner Chilcott Announces Receipt Paragraph Certification Notice
Warner Chilcott Announces Receipt Paragraph Certification Notices Warner Chilcott Announces Settlement Antitrust Suits Brought Certain
Warner Chilcott Announces Settlement Remaining Class Action Suit Warner Chilcott Announces Settlement Securities Litigation
Warner Chilcott Announces Shareholder Approval Irish Redomestication Warner Chilcott Barr Announce Settlement Femcon Patent Challenge
Warner Chilcott Considers Potential Repurchase Redemption 875 Senior Warner Chilcott Contacts
Warner Chilcott Files Lawsuit Against Barr Laboratories Inc Warner Chilcott Files Lawsuit Against Watson Laboratories Inc
Warner Chilcott Files Lawsuits Infringement Doryx Patent Warner Chilcott Files New Lawsuit Infringement Doryx Patent
Warner Chilcott Forward Looking Statements Warner Chilcott Limited
Warner Chilcott Plc Warner Chilcott Proposes Redomestication Bermuda Ireland
Warner Chilcott Reports Death Director James Andress Warner Chilcott Reports Operating Results 2007
Warner Chilcott Settles Suit Brought Federal Trade Warner Chilcotts Forward Looking Statements
What Being Asked Vote What Effect Failure Complete Reorganization Warner Chilcott
What Impact Reorganization Warner Chilcotts Current Debt Arrangements What Material Tax Consequences Transaction
What Matters Vote What Mean Receive Proxy Card
What Other Matters Come Annual Meeting What Other Matters Come Annual Meeting Special
What Quorum What Receive Warner Chilcott Limited Shares
What Vote Required Approve Each Proposal What Warner Chilcotts Corporate Presence Ireland
Winding Withholding Tax Dividends
Womens Healthcare 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki